Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | XBP1 | P17861 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20830999 | 0.92 | OPRM1 (0.36) | OPRM1OPRD1OPRK1PTGS1PTGS2 | |
| SCHEMBL23020008 | 0.87 | OPRM1 (0.35) | OPRM1OPRD1OPRK1PTGS1PTGS2 | |
| SCHEMBL17801960 | 0.80 | ITGB1 (0.34) | OPRM1OPRD1OPRK1PSEN1PSEN2 | |
| SCHEMBL17807576 | 0.80 | HTR2A (0.41) | ALDH1A1LMNAMAPTMAPK1HTT | |
| SCHEMBL26569584 | 0.78 | FPR3 (0.33) | OPRM1OPRD1OPRK1RAB9ALMNA | |
| SCHEMBL22698762 | 0.78 | MGLL (0.41) | OPRM1OPRD1OPRK1PTGS1PTGS2 | |
| SCHEMBL16834889 | 0.77 | PTGS1 (0.47) | OPRM1OPRD1OPRK1PTGS1PTGS2 | |
| SCHEMBL18100026 | 0.76 | MGLL (0.44) | OPRM1OPRD1OPRK1PTGS1PTGS2 | |
| SCHEMBL23889696 | 0.76 | KDM1A (0.32) | — | |
| SCHEMBL19684041 | 0.76 | KDM1A (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648315-B2 | Silvestrol antibody-drug conjugates and methods of use | GENENTECH, INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20200222545-A1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2020-07-16 | — | — | US | disclosed |
| US-10639378-B2 | Silvestrol antibody-drug conjugates and methods of use | GENENTECH, INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20170348422-A1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348422-A1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | SHBG, EPCAM, ITGAV | OPRM1 603/4885OPRD1 1019/4885OPRK1 588/4885 |
| US-20200222545-A1 | SILVESTROL ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | SHBG, EPCAM, ITGAV | OPRM1 603/4885OPRD1 1019/4885OPRK1 588/4885 |
| US-11648315-B2 | Silvestrol antibody-drug conjugates and methods of use | SHBG, EPCAM, ITGAV | OPRM1 603/4885OPRD1 1019/4885OPRK1 588/4885 |
| US-10639378-B2 | Silvestrol antibody-drug conjugates and methods of use | SHBG, EPCAM, ITGAV | OPRM1 603/4885OPRD1 1019/4885OPRK1 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.